Skip to main content
Free research Free research Free assay review with research home and workspace preview
Quick search ChEMBL 36
Assay Detail

CHEMBL5731471

Review assay metadata, readout intent, target linkage, and publication context from the same page.

Binding
In Vitro Affinity Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the β-arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 β-arrestin line results in the recruitment of β-arrestin (Richardson, R. M., R. J. Marjoram, L. S. Barak, R. Snyderman. 2003. Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with β-arrestin 2, a β-arrestin 2 recruitment test for CXCR2 or CXCR1 based on β-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44), as established by DiscoveRx Corporation was used. The stimulation of these two cell lines with CXCL8 (10 nM) induces β-arrestin 2 recruitment, as indicated by a significant increase in the induction factor. All the CXCR2 antagonists were tested in a dose-dependent manner and the concentration corresponding to 50% inhibition of the response was determined (IC50=half inhibition concentration).
30
Total Activities
7
Compounds Tested
3
Activity Types
0
Assay Parameters

Assay Information

Assay Type Binding
Confidence 8 — Homologous single protein target
Curated By Autocuration

Target

C-C chemokine receptor type 6 (CHEMBL4423)
Type SINGLE PROTEIN
Organism Homo sapiens

Publication

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
(2017)

Activity Statistics

Type Count Avg pChEMBL Best pChEMBL
IC50 10 8.24 8.80
kon 10 - -
k_off 10 - -

Compounds Tested

Compound Name Phase Activities Best pChEMBL
CHEMBL6049426 3 8.80
CHEMBL5979255 6 8.70
CHEMBL3952996 3 8.66
CHEMBL3951994 6 8.22
CHEMBL3901913 6 8.06
CHEMBL3904195 3 7.96
CHEMBL3909470 3 7.22

Activity Data

Compound Name Type Rel. Value Units pChEMBL
CHEMBL6049426 IC50 = 1.6 nM 8.80
CHEMBL5979255 IC50 = 2.0 nM 8.70
CHEMBL3952996 IC50 = 2.2 nM 8.66
CHEMBL5979255 IC50 = 2.2 nM 8.66
CHEMBL3951994 IC50 = 6.0 nM 8.22
CHEMBL3951994 IC50 = 8.0 nM 8.10
CHEMBL3901913 IC50 = 8.8 nM 8.06
CHEMBL3901913 IC50 = 9.7 nM 8.01
CHEMBL3904195 IC50 = 11.0 nM 7.96
CHEMBL3909470 IC50 = 60.0 nM 7.22
CHEMBL3901913 k_off = - s-1 -
CHEMBL3901913 kon = - -
CHEMBL3951994 k_off = - s-1 -
CHEMBL3951994 kon = - -
CHEMBL5979255 k_off = - s-1 -
CHEMBL5979255 kon = - -
CHEMBL3951994 k_off = - s-1 -
CHEMBL3951994 kon = - -
CHEMBL5979255 k_off = - s-1 -
CHEMBL5979255 kon = - -
CHEMBL6049426 kon = - -
CHEMBL6049426 k_off = - s-1 -
CHEMBL3909470 kon = - -
CHEMBL3952996 kon = - -
CHEMBL3909470 k_off = - s-1 -
CHEMBL3904195 kon = - -
CHEMBL3904195 k_off = - s-1 -
CHEMBL3952996 k_off = - s-1 -
CHEMBL3901913 kon = - -
CHEMBL3901913 k_off = - s-1 -